ImmuPharma currently has five lead compounds in development, each representing a potentially significant breakthrough in its field.


Lupuzor™, for the treatment of Lupus, recently received US FDA approval to enter Phase III with a Special Protocol Assessment and Fast Track designation.


ImmuPharma is publicly listed in London, trading under the symbol IMM, or IMM:LN on Bloomberg.


Our cancer treatment drug in development acts by preventing angiogenesis and proliferation.
WELCOME to ImmuPharma

ImmuPharma PLC is a pharmaceutical company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. The company’s most advanced drug candidate recently received the approval from the US FDA to enter phase III with a Special Protocol Assessment and “Fast Track” designation. ImmuPharma is led by a commercially focused Board and management team with extensive experience.

Share Price

Market Cap